The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A

Journal of Molecular Biology

Volumn 300, Issue 3, 2000, Pages 503-518

  Luciani, M G ^a   Hutchins, J R A ^a   Zheleva, D ^b   Hupp, T R ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b CYCLACEL LTD   (United Kingdom)

Author keywords

Cell cycle; Cyclin A; Kinase; p53; Radiation

Indexed keywords

ALANINE; CYCLIN A; CYCLIN B1; CYCLIN DEPENDENT KINASE INHIBITOR; DOCKING PROTEIN; ISOENZYME; PROTEIN P53;

ANIMAL CELL; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CELL DAMAGE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; HUMAN; HUMAN CELL; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RADIATION INJURY; TUMOR SUPPRESSOR GENE;

EID: 0034647433     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.2000.3830     Document Type: Article

References (54)

1. Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors
2. Retinoblastoma protein contains a C-terminal motif that targets it for phosphorylation by cyclin-cdk complexes
3. Recruitment of p300/CBP in p53-dependent signal pathways
4. Enhanced phosphorylation of p53 by ATM in response to DNA damage
5. Interactions of myogenic bHLH transcription factors with calcium-binding calmodulin and S100a (alpha alpha) proteins
6. DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site
7. Crystal structure and mutational analysis of the human CDK2 kinase complex with cell cycle-regulatory protein CksHs1
8. Mdm2 binding to a conformationally sensitive domain on p53 can be modulated by RNA
9. The multisubunit IkappaB kinase complex shows random sequential kinetics and is activated by the C-terminal domain of IkappaB alpha
10. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53
11. Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments
12. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations
13. Refined solution structure of the oligomerization domain of the tumour suppressor p53
14. An artificial cell-cycle inhibitor isolated from a combinatorial library
15. Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2
16. Novel phosphorylation sites of human turnout suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers
17. Dephosphorylation of human p53 at Ser20 in response to low doses of non-ionizing radiation
18. The in vitro phosphorylation of p53 by calcium-dependent protein kinase C-characterization of a protein-kinase-C-binding site on p53
19. Definition of a consensus binding site for p53
20. HSP70 binding sites in the tumor suppressor protein p53
21. Phosphorylation studies on rat p53 using the baculovirus expression system. Manipulation of the phosphorylation state with okadaic acid and influence on DNA binding
22. JNK targets p53 ubiquitination and degradation in nonstressed cells
23. Protein kinase CK2 interacts with a multi-protein binding domain of p53
24. Different peptide binding specificities of hsp70 family members
25. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors
26. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain
27. Modification of two distinct COOH-terminal domains is required for murine p53 activation by bacterial Hsp70
28. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases
29. Allosteric activation of latent p53 tetramers
30. Two distinct signaling pathways activate the latent DNA binding function of p53 in a casein kinase II-independent manner
31. Small peptides activate the latent sequence-specific DNA binding function of p53
32. Substrate specificity determinants of the checkpoint protein kinase Chk1
33. Covalent and noncovalent modifiers of the p53 protein
34. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain
35. Phosphorylation of p53 serine 15 increases interaction with CBP
36. Functional interplay between p53 and E2F through co-activator p300
37. Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53
38. Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2
39. Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo
40. Protein interactions at the carboxyl terminus of p53 result in the induction of its in vitro transactivation potential
41. Immunochemical analysis of the interaction of p53 with MDM2 fine mapping of the MDM2 binding site on p53 using synthetic peptides
42. Sequence-specific transcriptional activation is essential for growth suppression by p53
43. Purification and crystallization of human cyclin-dependent kinase 2
44. Structural basis of cyclin-dependent kinase activation by phosphorylation
45. Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53
46. Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A
47. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
48. DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization
49. A role for ATR in the DNA damage-induced phosphorylation of p53
50. Mutations in serines 15 and 20 of human p53 impair its apoptotic activity
51. Comparison between p53 staining in tissue sections and p53 proteins levels measured by an ELISA technique
52. Fine mapping and regulation of the association of p53 with p34cdc2
53. Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases
54. Post-translational modifications of p53 in replicative senescence overlapping but distinct from those induced by DNA damage